keyword
MENU ▼
Read by QxMD icon Read
search

NCCN

keyword
https://www.readbyqxmd.com/read/28612456/day-14-bone-marrow-examination-in-the-management-of-acute-myeloid-leukemia
#1
REVIEW
Christopher M Terry, Rory M Shallis, Elihu Estey, Seah H Lim
The National Comprehensive Cancer Network (NCCN) recommends that a repeat bone marrow evaluation is carried out seven to ten days following completion of induction therapy so that if a patient's day 14 bone marrow shows residual blast cell counts of >10%, the patient would proceed early to a second cycle of induction therapy. Although blast cell counts of <5% on day 14 bone marrow is sensitive in predicting remission on day 28, various studies have found that day 14 bone marrow is highly nonspecific because a large proportion of patients with blast cell counts of >5% on day 14 bone marrow would still attain a complete remission of the disease without any further chemotherapy...
June 13, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28606707/disparities-in-compliance-with-the-oncotype-dx-breast-cancer-test-in-the-united-states-a-national-cancer-data-base-assessment
#2
Zachary Kozick, Ammar Hashmi, James Dove, Marie Hunsinger, Tania Arora, Jeffrey Wild, Mohsen Shabahang, Joseph Blansfield
BACKGROUND: Oncotype DX (ODX) is a multi-gene tumor assay for breast cancer patients. Our objective is to assess whether eligible ODX patients received the test and whether recommendations were followed based on respective risk. METHODS: We retrospectively analyzed testing in patients deemed eligible for ODX using the National Cancer Data Base. RESULTS: A total of 158,235 patients met ODX eligibility criteria. Sixty-four percent of eligible patients did not receive the test...
June 9, 2017: American Journal of Surgery
https://www.readbyqxmd.com/read/28597183/discrepancies-between-nccn-and-esmo-guidelines-in-the-management-of-anal-cancer-a-qualitative-review
#3
REVIEW
Natalie Johnson, Gianluca Pellino, Constantinos Simillis, Shengyang Qiu, Stella Nikolaou, Daniel L Baird, Shahnawaz Rasheed, Paris P Tekkis, Christos Kontovounisios
There is an ever-growing need, with the ongoing developments in research and the progress towards patient centered care, to delineate standardized protocols of management of anal cancer. However, guidelines from different societies show some degree of disagreement. This is a systematic review of the literature to identify similarities and discrepancies between the guidelines for the management of anal cancer drafted by the European Society for Medical Oncology (ESMO) and by the National Comprehensive Cancer Network (NCCN)...
June 8, 2017: Updates in Surgery
https://www.readbyqxmd.com/read/28596266/nccn-news
#4
(no author information available yet)
No abstract text is available yet for this article.
June 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28596262/optimal-surveillance-strategies-after-surgery-for-renal-cell-carcinoma
#5
REVIEW
Mark D Tyson, Sam S Chang
One in 5 patients who undergo surgical resection for clinically localized renal cell carcinoma (RCC) develop local and/or distant recurrences which, when detected early, may be amenable to salvage local and systemic therapies. When considering that approximately half of these recurrences will occur during the first 2 years, a clear rationale exists for optimizing surveillance strategies after surgery. Although there is a notable dearth of high-quality data on this subject, clinical principles can guide clinicians as they attempt to balance the burden of surveillance strategies with potential clinical benefit...
June 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28596261/kidney-cancer-version-2-2017-nccn-clinical-practice-guidelines-in-oncology
#6
Robert J Motzer, Eric Jonasch, Neeraj Agarwal, Sam Bhayani, William P Bro, Sam S Chang, Toni K Choueiri, Brian A Costello, Ithaar H Derweesh, Mayer Fishman, Thomas H Gallagher, John L Gore, Steven L Hancock, Michael R Harrison, Won Kim, Christos Kyriakopoulos, Chad LaGrange, Elaine T Lam, Clayton Lau, M Dror Michaelson, Thomas Olencki, Phillip M Pierorazio, Elizabeth R Plimack, Bruce G Redman, Brian Shuch, Brad Somer, Guru Sonpavde, Jeffrey Sosman, Mary Dwyer, Rashmi Kumar
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These guidelines are developed by a multidisciplinary panel of leading experts from NCCN Member Institutions consisting of medical oncologists, hematologists and hematologic oncologists, radiation oncologists, urologists, and pathologists. The NCCN Guidelines are in continuous evolution and are updated annually or sometimes more often, if new high-quality clinical data become available in the interim...
June 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28596260/evaluating-the-nccn-clinical-criteria-for-recommending-brca1-and-brca2-genetic-testing-in-patients-with-breast-cancer
#7
Caiqian Cropper, Ashley Woodson, Banu Arun, Carlos Barcenas, Jennifer Litton, Sarah Noblin, Diane Liu, Minjeong Park, Molly Daniels
Background: Mutations in the BRCA1 and BRCA2 genes predispose individuals to a significantly elevated risk for breast and ovarian cancers. Identification of these individuals allows for proper screening, management, and testing of at-risk relatives. NCCN has established clinical criteria for recommending BRCA1/2 testing. Patients and Methods: A retrospective chart review of 1,123 patients with breast cancer was performed to evaluate the positive predictive values (PPVs) of 14 individual criteria for predicting BRCA1/2 mutations...
June 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28596258/overuse-of-chest-ct-in-patients-with-stage-i-and-ii-breast-cancer-an-opportunity-to-increase-guidelines-compliance-at-an-nccn-member-institution
#8
Barbara Dull, Andrew Linkugel, Julie A Margenthaler, Amy E Cyr
Background: The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) recommend that patients with clinical stage I/II breast cancer undergo advanced imaging for staging only when symptomatic. Regardless, many asymptomatic patients undergo chest CT. The goal of this study was to assess the use and results of chest CT in these patients at an NCCN Member Institution. Methods: Patients with breast cancer diagnosed between 1998 and 2012 were identified in a prospectively maintained database. All patients with clinical stage I/II disease who did not receive neoadjuvant chemotherapy were included...
June 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28596257/developments-in-molecular-testing-and-biosimilars
#9
Katy Winckworth-Prejsnar, Elizabeth A Nardi, Lisa Korin Lentz, Jeffrey A Crawford, C Lyn Fitzgerald, Robert W Carlson
Molecular testing and biosimilars offer the potential for increased access to targeted treatment options and reduction in healthcare costs, but come with significant challenges in ensuring patient access to innovation in cancer care while maintaining safe, effective, ethical, and affordable treatment options. As providers, payers, patients, and the larger healthcare systems become inundated with a wide variety of molecular diagnostics and an increased number of biosimilars coming to market, it will be important to understand regulatory guidance and policy implications relating to the appropriateness of molecular testing and the clinical use of biosimilars in cancer care...
June 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28596256/nccn-guidelines-insights-head-and-neck-cancers-version-2-2017
#10
David Adelstein, Maura L Gillison, David G Pfister, Sharon Spencer, Douglas Adkins, David M Brizel, Barbara Burtness, Paul M Busse, Jimmy J Caudell, Anthony J Cmelak, A Dimitrios Colevas, David W Eisele, Moon Fenton, Robert L Foote, Jill Gilbert, Robert I Haddad, Wesley L Hicks, Ying J Hitchcock, Antonio Jimeno, Debra Leizman, William M Lydiatt, Ellie Maghami, Loren K Mell, Bharat B Mittal, Harlan A Pinto, John A Ridge, James Rocco, Cristina P Rodriguez, Jatin P Shah, Randal S Weber, Matthew Witek, Frank Worden, Sue S Yom, Weining Zhen, Jennifer L Burns, Susan D Darlow
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck Cancers provide treatment recommendations for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary sinuses, and salivary glands. Recommendations are also provided for occult primary of the head and neck (H&N), and separate algorithms have been developed by the panel for very advanced H&N cancers. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding the increase in human papillomavirus-associated oropharyngeal cancer and the availability of immunotherapy agents for treatment of patients with recurrent or metastatic H&N cancer...
June 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28596016/multi-disciplinary-summit-on-genetics-services-for-women-with-gynecologic-cancers-a-society-of-gynecologic-oncology-white-paper
#11
Leslie M Randall, Bhavana Pothuri, Elizabeth M Swisher, John P Diaz, Adam Buchanan, Catherine T Witkop, C Bethan Powell, Ellen Blair Smith, Mark E Robson, Jeff Boyd, Robert L Coleman, Karen Lu
OBJECTIVE: To assess current practice, advise minimum standards, and identify educational gaps relevant to genetic screening, counseling, and testing of women affected by gynecologic cancers. METHODS: The Society of Gynecologic Oncology (SGO) organized a multidisciplinary summit that included representatives from the American College of Obstetricians and Gynecologists (ACOG), the American Society Clinical Oncology (ASCO), the National Society of Genetic Counselors (NSGC), and patient advocacy groups, BrightPink and Facing our Risk of Cancer Empowered (FORCE)...
June 7, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28594887/study-of-structural-stability-and-damaging-effect-on-membrane-for-four-a%C3%AE-42-dimers
#12
Wei Feng, Huimin Lei, Jiarui Si, Tao Zhang
Increasing evidence shows that Aβ oligomers are key pathogenic molecules in Alzheimer's disease. Among Aβ oligomers, dimer is the smallest aggregate and toxic unit. Therefore, understanding its structural and dynamic properties is quite useful to prevent the formation and toxicity of the Aβ oligomers. In this study, we performed molecular dynamic simulations on four Aβ42 dimers, 2NCb, CNNC, NCNC and NCCN, within the hydrated DPPC membrane. Four Aβ42 dimers differ in the arrangements of two Aβ42 peptides...
2017: PloS One
https://www.readbyqxmd.com/read/28589400/radical-prostatectomy-for-high-risk-localized-or-node-positive-prostate-cancer-removing-the-primary
#13
REVIEW
Justin T Matulay, G Joel DeCastro
PURPOSE OF REVIEW: We reviewed the literature to determine what role, if any, radical prostatectomy should play in the treatment of high-risk and/or node-positive prostate cancer. RECENT FINDINGS: The AUA, NCCN, and EAU all include radical prostatectomy as a treatment option for high-risk prostate cancer based on evidence that has shown improvements in biochemical-free and disease-specific survival. Lymph node-positive patients may also derive benefit from radical prostatectomy with lymph node dissection, however, only retrospective studies with high risk of selection bias have been published to date...
July 2017: Current Urology Reports
https://www.readbyqxmd.com/read/28573517/video-education-on-hereditary-breast-and-ovarian-cancer-hboc-for-physicians-an-interventional-study
#14
Bhuma Krishnamachari, Mahin Rehman, Jason E Cohn, Vivian Chan, Neil Modi, Ofri Leitner, Kelly Tangney, April O'Connor, William Blazey, Sharon Koehler, David Tegay
The National Comprehensive Cancer Network (NCCN) guidelines are the gold standard in hereditary cancer risk assessment, screening, and treatment. A minority of physicians follow NCCN guidelines for BRCA1 or BRCA2 mutations. This study assesses the impact of an interventional educational program on HBOC in terms of knowledge. Physicians were sent an invite to join either an intervention survey (web-training offered prior to the knowledge survey) or control survey (web-training offered after the knowledge survey)...
June 1, 2017: Journal of Cancer Education: the Official Journal of the American Association for Cancer Education
https://www.readbyqxmd.com/read/28571145/morphological-changes-in-bone-marrow-post-imatinib-therapy-in-chronic-phase-cml-a-follow-up-study-on-sequential-bone-marrow-aspirates-and-biopsies
#15
Neha Chopra Narang, Usha Rusia, Meera Sikka, Mrinalini Kotru
INTRODUCTION: Imatinib mesylate is used extensively for first line treatment of Chronic Myeloid Leukemia (CML). However, not many studies have documented morphological changes in bone marrow biopsies produced during Imatinib therapy with reference to myelofibrosis. AIM: To document the morphological changes produced in the bone marrow during Imatinib therapy. MATERIALS AND METHODS: This longitudinal study followed up 75 Philadelphia Chromosome Positive Chronic Myeloid Leukemia with chronic phase(Ph+ CML- CP) patients sequentially, receiving 400-600mg Imatinib over a period of 12 or more months...
April 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28552819/prostate-cancer-antigen-3-pca3-score-does-not-predict-for-adverse-pathologic-features-at-radical-prostatectomy-or-for-progression-free-survival-in-clinically-localized-intermediate-and-high-risk-prostate-cancer
#16
John V Hegde, Darlene Veruttipong, Jonathan W Said, Robert E Reiter, Michael L Steinberg, Christopher R King, Amar U Kishan
OBJECTIVES: To evaluate whether pre-operative urinary prostate cancer antigen 3 (PCA3) scores predict for adverse pathologic features (APFs) and/or progression-free survival (PFS) in men with intermediate- or high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP). METHODS: One-hundred-nine men with intermediate- (n=52) or high-risk (n=57) PCa who underwent RP were retrospectively identified. Logistic regression analysis was performed to evaluate the association of PCA3 score with various APFs (e...
May 25, 2017: Urology
https://www.readbyqxmd.com/read/28535104/measuring-the-value-of-new-drugs-validity-and-reliability-of-4-value-assessment-frameworks-in-the-oncology-setting
#17
Tanya G K Bentley, Joshua T Cohen, Elena B Elkin, Julie Huynh, Arnab Mukherjea, Thanh H Neville, Matthew Mei, Ronda Copher, Russell Knoth, Ioana Popescu, Jackie Lee, Jenelle M Zambrano, Michael S Broder
BACKGROUND: Several organizations have developed frameworks to systematically assess the value of new drugs. OBJECTIVE: To evaluate the convergent validity and interrater reliability of 4 value frameworks to understand the extent to which these tools can facilitate value-based treatment decisions in oncology. METHODS: Eight panelists used the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), Institute for Clinical and Economic Review (ICER), and National Comprehensive Cancer Network (NCCN) frameworks to conduct value assessments of 15 drugs for advanced lung and breast cancers and castration-refractory prostate cancer...
June 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28535103/value-frameworks-for-the-patient-provider-interaction-a-comparison-of-the-asco-value-framework-versus-nccn-evidence-blocks-in-determining-value-in-oncology
#18
Bijal Shah-Manek, Joseph S Galanto, Huong Nguyen, Robert Ignoffo
BACKGROUND: To address the rising concern about oncology drug costs, the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) recently developed unique tools to help providers and patients make informed decisions about the value of an anticancer regimen. The ASCO Value Framework (AVF) allows users to generate a net health benefit (NHB) score along with drug acquisition costs for oncology regimens that have been compared in a prospective randomized clinical trial...
June 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28528518/a-multi-gene-panel-study-in-hereditary-breast-and-ovarian-cancer-in-colombia
#19
A M Cock-Rada, C A Ossa, H I Garcia, L R Gomez
Germline mutations in BRCA1 and BRCA2 account for approximately 50% of inherited breast and ovarian cancers. Three founder mutations in BRCA1/2 have been reported in Colombia, but the pattern of mutations in other cancer susceptibility genes is unknown. This study describes the frequency and type of germline mutations in hereditary breast and/or ovarian cancer genes in a referral cancer center in Colombia. Eighty-five women referred to the oncogenetics unit of the Instituto de Cancerologia Las Americas in Medellin (Colombia), meeting testing criteria for hereditary breast and ovarian cancer syndrome (NCCN 2015), who had germline testing with a commercial 25-gene hereditary cancer panel, were included in the analysis...
May 20, 2017: Familial Cancer
https://www.readbyqxmd.com/read/28521361/hypofractionated-radiotherapy-for-patients-with-early-stage-glottic-cancer-patterns-of-care-and-survival
#20
Trevor J Bledsoe, Henry S Park, John M Stahl, Wendell G Yarbrough, Barbara A Burtness, Roy H Decker, Zain A Husain
Background: Radiotherapy alone is often used to treat early-stage glottic cancer (ESGC); however, the optimal radiation treatment schedule remains unknown. The National Comprehensive Cancer Network (NCCN) guidelines recommend both hypofractionated radiotherapy (HFX) and conventionally fractionated radiotherapy (CFX). We compared overall survival (OS) and treatment patterns among patients treated with HFX vs CFX for ESGC using a large national database. Methods: We identified patients diagnosed with stage I-II (cT1-2N0M0) glottic cancer from 2004 to 2013 within the National Cancer Data Base who were treated with either HFX (2...
October 1, 2017: Journal of the National Cancer Institute
keyword
keyword
30821
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"